Revenue Breakdown
Composition ()
No data
Revenue Streams
Supernus Pharmaceuticals Inc (SUPN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Net product sales-Qelbree, accounting for 46.9% of total sales, equivalent to $77.55M. Other significant revenue streams include Net product sales - GOCOVRI and Net product sales-APOKYN. Understanding this composition is critical for investors evaluating how SUPN navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Supernus Pharmaceuticals Inc maintains a gross margin of 77.53%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 6.53%, while the net margin is -1.94%. These profitability ratios, combined with a Return on Equity (ROE) of -3.68%, provide a clear picture of how effectively SUPN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, SUPN competes directly with industry leaders such as TARS and VRDN. With a market capitalization of $3.17B, it holds a significant position in the sector. When comparing efficiency, SUPN's gross margin of 77.53% stands against TARS's 92.80% and VRDN's 100.00%. Such benchmarking helps identify whether Supernus Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
